Sriram Sathyanarayanan - 19 Jan 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Role: Chief Scientific Officer
Signature: /s/ Yalonda Howze, Attorney-in-Fact for Sriram Sathyanarayanan
Issuer symbol: N/A
Transactions as of: 19 Jan 2023
Net transactions value: -$622
Form type: 4
Filing time: 23 Jan 2023, 15:36:00 UTC
Previous filing: 20 Sep 2022
Next filing: 26 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDAKQ	Common Stock	Options Exercise		+2,834			2,834	19 Jan 2023	Direct	F1
transaction	CDAKQ	Common Stock	Sale	$622	-1,082	-38%	$0.5751^*	1,752	20 Jan 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDAKQ	Restricted Stock Units	Options Exercise	$0	-2,834	-33%	$0.000000	5,666	19 Jan 2023	Common Stock	2,834		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3	Each RSU represents a contingent right to receive one share of common stock.
F4	On January 19, 2022, the reporting person was granted 8,500 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.